Products with
Inhibitors bioactivity
Cat.No.
|
Product Name
|
BCN1051 |
Daphnetin
|
Daphnetin is a dihydroxycoumarin that is being used in China for the treatment of coagulation disorders, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit antimalarial, anti-rheumatoid arthritis, anti-proliferative, anti-inflammatory and anti-oxidant activities. it is also a chelator and an antioxidant. Daphnetin can enhance immunological functions of B lymphocytes, the expression of IL-12 in B lymphocytes can be up-regulated by daphnetin through natural immunity approach. |
BCN1056 |
Helicid
|
Helicid analogues are mushroom tyrosinase inhibitors, some of them have more potent inhibitory activities than arbutin (IC50 =7.3 mM).Some helicid analogues exhibit potent cholinesterase (AChE) inhibitory activities. |
BCN1057 |
(-)-Huperzine A
|
(-)-Huperzine A is a naturally occurring potent reversible AChE inhibitor that penetrates the blood-brain barrier, it also has several neuroprotective effects including modification of beta-amyloid peptide, reduction of oxidative stress, anti-inflammatory, anti-apoptotic and induction and regulation of nerve growth factor. |
BCN1058 |
Huperzine A
|
Huperzine A is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).Huperzine A induces CYP3A4 expression and activation via PXR dependent pathways, may contribute to drug-drug interactions with ligustrazine and oridonin. |
BCN1059 |
Huperzine B
|
Huperzine B is a efficient inhibitor of human brain AChE, it can enhance ognitive and protect neuro, may be potentially new drug candidates for Alzheimer's disease therapy. |